We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Carl Zeiss Acquires Bio-Rad's Cell Science Division

By Biotechdaily staff writers
Posted on 15 Jun 2004
In a move that will enlarge its microscopy business, Carl Zeiss (Oberkochen, Germany) has acquired the Cell Science Division (Hemel Hempstead, UK) of Bio-Rad Laboratories, Inc. More...
(Hercules, CA, USA). Terms were not disclosed.

This strategic move is part of the ongoing investment in enhancing the application expertise at Carl Zeiss, according to the company. The acquisition is expected to accelerate future advances in confocal and multiphoton microscope instrumentation with Carl Zeiss as the major driving force in the field.

"Today, Carl Zeiss stands for high-end laser scanning microscopes that are benchmark solutions for advanced applications in 3-D microscopy,” said Dr. Ulrich Simon, head of the microscopy business group at Carl Zeiss. "Joining our forces will strengthen our relationship with Zeiss and Bio-Rad customers, and will allow a considerable additional refinement of both companies' worldwide service and support network.”





Related Links:
Carl Zeiss
Bio-Rad

New
Gold Member
Aspiration System
VACUSAFE
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.